Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Cellectis S.A. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 27 | 29 | +2 |
| Shares | 9.77M | 12.8M | +2.99M (+30.6%) |
| Value | $20.9M | $23.0M | +$2.10M (+10.1%) |
New holders (6)
Institutions that held Cellectis S.A. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| B Group, Inc. | 3,081,501 | $5.55M | 3.39% |
| Millennium Management LLC | 534,551 | $962.2K | 0.00% |
| UBS Group AG | 229,081 | $412.3K | 0.00% |
| Acadian Asset Management LLC | 19,916 | $34.0K | 0.00% |
| Advisor Group Holdings, Inc. | 303 | $546 | 0.00% |
| Principal Securities, Inc. | 52 | $94 | 0.00% |
Sold out (4)
Institutions that held Cellectis S.A. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Principal Financial Group Inc | 411,800 | $881.3K |
| KBC Group NV | 163,447 | $347.0K |
| Susquehanna International Group, LLP | 13,010 | $27.8K |
| BlackRock, Inc. | 2,755 | $5.84K |